SABCS Voice of China丨Professor Jian Zhang: Orally Administered SERD That Can Cross the Blood-Brain Barrier Challenges the Dilemma of Endocrine Treatment for ER+/HER2- Advanced Breast Cancer
The 46th San Antonio Breast Cancer Symposium (SABCS), a prestigious academic event in the field of international breast cancer, was held from December 5th to 9th in San Antonio, Texas, USA. A Phase I clinical study of a new selective estrogen receptor degrader (SERD) led by Professor Jiong Wu and Professor Jian Zhang 's team from Fudan University Shanghai Cancer Center was selected for the SABCS Poster Spotlight and was orally presented by Professor Jian Zhang on December 7th, with Professor Wu Jiong answering questions on site. SIM0270, a novel SERD capable of crossing the blood-brain barrier, demonstrated good tolerability and antitumor activity in its first human Phase I clinical trial among patients with advanced or metastatic ER+/HER2- who had failed multiple lines of treatment.